Daewoong Pharmaceutical Co., Ltd.(KR:069620)
â‚©100,700.00-1200.00 (-1.18%)
KR:069620
Daewoong Pharmaceutical Co., Ltd. financials statements
â‚©100,700.00
At close:-1200.00 (-1.18%)
Want to see KR:069620 full AI Analyst Report?
Daewoong Pharmaceutical Co., Ltd. (069620) Ratios
Daewoong Pharmaceutical Co., Ltd. Ratios
KR:069620's free cash flow for Q3 2026 was ₩-16.93B. For the 2026 fiscal year, KR:069620's free cash flow was decreased by ₩-46.69B and operating cash flow was ₩29.76B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.24 | 0.97 | 0.92 | 1.16 | 1.13 |
| Quick Ratio | 0.72 | 0.57 | 0.53 | 0.72 | 0.75 |
| Cash Ratio | 0.29 | 0.16 | 0.18 | 0.22 | 0.16 |
| Solvency Ratio | 0.20 | 0.07 | 0.19 | 0.10 | 0.09 |
| Operating Cash Flow Ratio | 0.25 | 0.08 | 0.22 | 0.25 | 0.09 |
| Short-Term Operating Cash Flow Coverage | 0.54 | 0.16 | 0.34 | 0.51 | 0.16 |
| Net Current Asset Value | â‚© -495.79B | â‚© -437.20B | â‚© -283.21B | â‚© -273.15B | â‚© -192.37B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.35 | 0.33 | 0.27 | 0.29 | 0.31 |
| Debt-to-Equity Ratio | 0.82 | 0.82 | 0.61 | 0.73 | 0.78 |
| Debt-to-Capital Ratio | 0.45 | 0.45 | 0.38 | 0.42 | 0.44 |
| Long-Term Debt-to-Capital Ratio | 0.35 | 0.29 | 0.08 | 0.25 | 0.24 |
| Financial Leverage Ratio | 2.35 | 2.49 | 2.31 | 2.57 | 2.47 |
| Debt Service Coverage Ratio | 0.85 | 0.24 | 0.39 | 0.36 | 0.30 |
| Interest Coverage Ratio | 15.67 | 21.18 | 9.21 | 11.40 | 8.66 |
| Debt to Market Cap | 0.41 | 0.44 | 0.35 | 0.25 | 0.27 |
| Interest Debt Per Share | 72656.03 | 57034.20 | 42264.97 | 41116.33 | 41430.58 |
| Net Debt to EBITDA | 2.69 | 4.86 | 2.17 | 4.04 | 5.35 |
| Profitability Margins | |||||
| Gross Profit Margin | 51.74% | 51.60% | 49.96% | 49.91% | 47.25% |
| EBIT Margin | 12.45% | 4.47% | 8.81% | 3.68% | 7.70% |
| EBITDA Margin | 15.65% | 7.91% | 11.99% | 6.65% | 5.99% |
| Operating Profit Margin | 12.45% | 10.40% | 8.81% | 7.48% | 7.70% |
| Pretax Profit Margin | 12.21% | 3.97% | 8.87% | 2.99% | 1.71% |
| Net Profit Margin | 12.47% | 1.74% | 8.85% | 3.30% | 2.13% |
| Continuous Operations Profit Margin | 12.28% | 1.64% | 8.73% | 3.06% | 2.61% |
| Net Income Per EBT | 102.10% | 43.74% | 99.79% | 110.20% | 124.01% |
| EBT Per EBIT | 98.12% | 38.22% | 100.73% | 40.01% | 22.27% |
| Return on Assets (ROA) | 8.29% | 1.25% | 6.88% | 2.70% | 1.73% |
| Return on Equity (ROE) | 19.47% | 3.11% | 15.87% | 6.95% | 4.27% |
| Return on Capital Employed (ROCE) | 11.02% | 10.98% | 10.59% | 8.78% | 9.30% |
| Return on Invested Capital (ROIC) | 9.52% | 3.65% | 7.70% | 7.23% | 7.35% |
| Return on Tangible Assets | 9.82% | 1.52% | 8.27% | 3.26% | 2.06% |
| Earnings Yield | 9.81% | 1.70% | 9.08% | 2.38% | 1.50% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.73 | 6.63 | 7.47 | 6.89 | 7.11 |
| Payables Turnover | 7.14 | 8.29 | 6.81 | 7.69 | 8.58 |
| Inventory Turnover | 2.44 | 2.69 | 2.85 | 3.07 | 3.47 |
| Fixed Asset Turnover | 1.86 | 2.11 | 2.64 | 2.90 | 2.91 |
| Asset Turnover | 0.66 | 0.72 | 0.78 | 0.82 | 0.81 |
| Working Capital Turnover Ratio | 24.76 | -41.77 | 111.64 | 18.84 | 8.82 |
| Cash Conversion Cycle | 152.73 | 146.97 | 123.32 | 124.30 | 113.87 |
| Days of Sales Outstanding | 54.20 | 55.09 | 48.83 | 52.94 | 51.33 |
| Days of Inventory Outstanding | 149.69 | 135.90 | 128.10 | 118.83 | 105.05 |
| Days of Payables Outstanding | 51.15 | 44.02 | 53.62 | 47.48 | 42.52 |
| Operating Cycle | 203.89 | 190.99 | 176.94 | 171.78 | 156.38 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 12876.97 | 4475.26 | 11905.53 | 10679.79 | 3634.19 |
| Free Cash Flow Per Share | -3653.12 | -15427.66 | 2334.64 | 443.20 | -3162.20 |
| Dividend Paid and CapEx Coverage Ratio | 0.75 | 0.22 | 1.17 | 0.99 | 0.49 |
| Capital Expenditure Coverage Ratio | 0.78 | 0.22 | 1.24 | 1.04 | 0.53 |
| Operating Cash Flow Coverage Ratio | 0.18 | 0.08 | 0.29 | 0.26 | 0.09 |
| Operating Cash Flow to Sales Ratio | 0.09 | 0.04 | 0.10 | 0.09 | 0.03 |
| Free Cash Flow Yield | -2.12% | -12.21% | 1.99% | 0.28% | -2.14% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.12 | 58.79 | 11.02 | 42.06 | 66.46 |
| Price-to-Sales (P/S) Ratio | 1.27 | 1.02 | 0.98 | 1.39 | 1.41 |
| Price-to-Book (P/B) Ratio | 1.98 | 1.83 | 1.75 | 2.92 | 2.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -47.17 | -8.19 | 50.29 | 362.14 | -46.80 |
| Price-to-Operating Cash Flow Ratio | 13.38 | 28.24 | 9.86 | 15.03 | 40.72 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.74 | 0.06 | 0.59 | 0.77 |
| Enterprise Value Multiple | 10.81 | 17.78 | 10.30 | 24.91 | 28.93 |
| Enterprise Value | 2.66T | 2.00T | 1.70T | 2.12T | 2.00T |
| EV to EBITDA | 10.81 | 17.78 | 10.30 | 24.91 | 28.93 |
| EV to Sales | 1.69 | 1.41 | 1.24 | 1.66 | 1.73 |
| EV to Free Cash Flow | -62.77 | -11.27 | 63.72 | 432.21 | -57.43 |
| EV to Operating Cash Flow | 17.81 | 38.85 | 12.49 | 17.94 | 49.97 |
| Tangible Book Value Per Share | 66206.24 | 50432.37 | 53816.19 | 42932.09 | 43365.62 |
| Shareholders’ Equity Per Share | 86829.49 | 69063.08 | 67165.90 | 54929.75 | 52118.72 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.59 | 0.02 | -0.02 | -0.52 |
| Revenue Per Share | 135573.15 | 123647.08 | 120389.42 | 115646.57 | 104768.35 |
| Net Income Per Share | 16903.04 | 2149.71 | 10656.40 | 3816.02 | 2226.78 |
| Tax Burden | 1.02 | 0.44 | 1.00 | 1.10 | 1.24 |
| Interest Burden | 0.98 | 0.89 | 1.01 | 0.81 | 0.22 |
| Research & Development to Revenue | 0.11 | 0.12 | 0.12 | 0.13 | 0.11 |
| SG&A to Revenue | 0.19 | 0.19 | 0.28 | 0.19 | 0.19 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.76 | 2.21 | 1.12 | 3.02 | 1.32 |
Currency in KRW

